Published in Biostatistics on June 07, 2010
Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med (2013) 4.45
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev (2011) 2.25
Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care (2013) 1.88
The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control (2012) 1.36
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med (2014) 1.32
Expected population impacts of discontinued prostate-specific antigen screening. Cancer (2014) 1.24
Risk stratification in prostate cancer screening. Nat Rev Urol (2012) 1.13
Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. JAMA Oncol (2016) 1.04
Individualized estimates of overdiagnosis in screen-detected prostate cancer. J Natl Cancer Inst (2014) 1.04
Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial. J Natl Cancer Inst (2013) 0.95
Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. Int J Cancer (2014) 0.94
Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer. Cancer Epidemiol Biomarkers Prev (2015) 0.88
Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality. J Natl Cancer Inst Monogr (2013) 0.82
Longitudinal multistage model for lung cancer incidence, mortality, and CT detected indolent and aggressive cancers. Math Biosci (2012) 0.81
Screening men at increased risk for prostate cancer diagnosis: Model estimates of benefits and harms. Cancer Epidemiol Biomarkers Prev (2016) 0.78
Is prostate cancer different in black men? Answers from 3 natural history models. Cancer (2017) 0.75
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA (1995) 8.60
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2008) 8.14
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst (2009) 6.96
Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA (1993) 5.77
Multistage carcinogenesis and the incidence of colorectal cancer. Proc Natl Acad Sci U S A (2002) 3.64
Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol (2006) 3.53
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst (2005) 2.82
A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol (2000) 2.46
A population model of prostate cancer incidence. Stat Med (2006) 2.44
Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer (2007) 2.31
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol (2005) 2.24
The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol (2000) 2.13
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics (2007) 2.09
Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making (2008) 2.06
Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst (1995) 1.96
Lead time associated with screening for prostate cancer. Int J Cancer (2004) 1.93
Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol (1998) 1.68
The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing. Stat Methods Med Res (2004) 1.39
Modeling Disease Progression with Longitudinal Markers. J Am Stat Assoc (2008) 1.13
Age-specific reference ranges for serum prostate-specific antigen. Urology (1995) 1.12
The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men. Br J Urol (1998) 0.89
Simulation-based parameter estimation for complex models: a breast cancer natural history modelling illustration. Stat Methods Med Res (2004) 0.87
Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer. J Urol (2001) 0.79
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst (2009) 6.96
Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care (2002) 4.88
Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med (2013) 4.45
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol (2011) 2.46
Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer (2007) 2.31
Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst (2014) 2.30
What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev (2011) 2.25
Studies of prostate-cancer mortality: caution advised. Lancet Oncol (2008) 2.22
Models in the development of clinical practice guidelines. Ann Intern Med (2014) 2.18
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics (2007) 2.09
Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med (2014) 1.87
Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med (2003) 1.79
Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr (2006) 1.73
Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology (2004) 1.71
It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. J Urol (2008) 1.66
Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiol Biomarkers Prev (2002) 1.60
Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer (2006) 1.60
Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst (2011) 1.58
Combining results of microarray experiments: a rank aggregation approach. Stat Appl Genet Mol Biol (2006) 1.56
Modeling grade progression in an active surveillance study. Stat Med (2013) 1.41
Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia? Am J Epidemiol (2013) 1.41
The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model. Ann Intern Med (2016) 1.41
Combining longitudinal studies of PSA. Biostatistics (2004) 1.40
The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing. Stat Methods Med Res (2004) 1.39
Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Med Care (2007) 1.38
The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control (2012) 1.36
Cluster-based network model for time-course gene expression data. Biostatistics (2006) 1.35
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med (2014) 1.32
Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res (2012) 1.25
Expected population impacts of discontinued prostate-specific antigen screening. Cancer (2014) 1.24
Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.14
Methods for Assessing Improvement in Specificity when a Biomarker is Combined with a Standard Screening Test. Stat Biopharm Res (2009) 1.13
Association of insurance and race/ethnicity with disease severity among men diagnosed with prostate cancer, National Cancer Database 2004-2006. Cancer Epidemiol Biomarkers Prev (2010) 1.12
An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol (2004) 1.09
Individualized estimates of overdiagnosis in screen-detected prostate cancer. J Natl Cancer Inst (2014) 1.04
Surveillance endoscopy does not improve survival for patients with local and regional stage colorectal cancer. Cancer (2007) 1.02
Differential expression and network inferences through functional data modeling. Biometrics (2008) 1.00
What happens after an elevated PSA test: the experience of 13,591 veterans. J Gen Intern Med (2010) 0.99
Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev (2003) 0.96
Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial. J Natl Cancer Inst (2013) 0.95
Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. Int J Cancer (2014) 0.94
Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma. Int J Cancer (2005) 0.94
Advanced diagnostic breast cancer imaging: variation and patterns of care in Washington state. J Oncol Pract (2013) 0.93
Depression and incident lower limb amputations in veterans with diabetes. J Diabetes Complications (2010) 0.91
Estimating the influence of rescreening interval on the benefits associated with cancer screening: approaches and limitations. Epidemiology (2002) 0.90
IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. Prostate (2005) 0.89
Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer. Gastroenterology (2003) 0.87
Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States. Cancer Epidemiol Biomarkers Prev (2009) 0.86
Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer. Am J Gastroenterol (2002) 0.86
AUDIT-C alcohol screening results and postoperative inpatient health care use. J Am Coll Surg (2012) 0.82
Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer. Int J Cancer (2003) 0.81
Building better models: if we build them, will policy makers use them? Toward integrating modeling into health care decisions. Med Decis Making (2012) 0.79
Estimated impact of the prostate cancer prevention trial on population mortality. Cancer (2005) 0.78
Biopsy follow-up of prostate-specific antigen tests. Am J Prev Med (2012) 0.77
Case-control studies of the efficacy of cancer screening: overcoming bias from nonrandom patterns of screening. Epidemiology (2004) 0.77
Biological correlates of biochemical recurrence free survival using multiple markers in a large tissue microarray cohort. Ann Clin Lab Sci (2013) 0.76
Alternative prostate cancer screening strategies--in response. Ann Intern Med (2013) 0.75
Much ado about mammography variability. J Natl Cancer Inst (2002) 0.75
Predictors of preoperative MRI for breast cancer: differences by data source. J Comp Eff Res (2015) 0.75
Case-control studies of cancer surveillance procedures. J Clin Epidemiol (2011) 0.75
Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies. Am J Epidemiol (2016) 0.75
Models in the development of clinical practice guidelines. Ann Intern Med (2015) 0.75